echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Johnson & Johnson abandons Erleada, Zytiga prostate cancer combination therapy regulatory application

    Johnson & Johnson abandons Erleada, Zytiga prostate cancer combination therapy regulatory application

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationFan Dongdong

    After failing to reach the secondary endpoint of the key Phase III trial, Johnson & Johnson stated that it will not seek a regulatory application for the prostate cancer drug combination Erleada and Zytiga in the future.


    Johnson & Johnson made this decision based on the results of the Phase III ACIS trial of the prostate cancer drug combination Erleada and Zytiga, which was published at the American Society of Clinical Oncology Symposium on Genitourinary Cancer in February this year.


    In the trial, all subjects were divided into two groups, and they were treated with the combination of Erleada, Zytiga, and prednisone, or a placebo, ZYTIGA, and prednisone.


    However, this test is not a complete failure.


    The entire ACIS study population is heterogeneous in terms of androgen receptor (AR) resistance and sensitivity markers.


    In this regard, Johnson & Johnson concluded that the combination therapy Erleada and Zytiga for prostate cancer did not show "significant clinical benefits" in the key secondary endpoints, including prolonging the life of patients, improving the long-term use of opioids, and improving the start The time of cytotoxic chemotherapy and the time of pain development, etc.


    However, Johnson & Johnson also emphasized that this decision does not mean that the company will completely abandon the research and development results of Erleada and Zytiga.


    As a new generation of androgen receptor (AR) inhibitor, Erleada, the world's first drug for the treatment of nmCRPC, can block the activity of male hormones (such as testosterone hormone) and delay the progression of the disease.


    Since the introduction of generic drugs in late 2018, generic drugs have been suppressing Johnson & Johnson's Zytiga revenue.


    Reference source:

    Reference source:

    1.


    1.


    2.


    3.
    Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.